The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer
This study aimed to estimate the incremental lifetime effects, costs, and net monetary benefit (NMB) of knowing Incremental NMB (INMB) was calculated as the average net monetized benefit of knowing Knowing BRCA information for ROC patients provided an additional monetized value of $3,528 in (payer) and $3,194 (society). Escalated to all ROC patients in the U.S. and future incidence ROC estimates, knowing The economic value of knowing
